Shanghai Haohai Biological Technology Co., Ltd. Class A

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H carries a market capitalization of 7.66B, placing it among publicly traded companies globally. Its enterprise value stands at 5.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Haohai Biological Technology Co., Ltd. Class H's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H has 500.12M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H maintains a current ratio of 3.49, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H's stock has declined approximately 42.50% over the past 52 weeks. The 50-day moving average sits at 16.22, while the 200-day moving average is 20.04.

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H holds 2.77B in cash and equivalents against 512.27M in total debt, resulting in a net debt position of -2.21B. Total book value stands at 6.13B, with working capital of 2.76B providing operational flexibility.

Shanghai Haohai Biological Technology Co., Ltd. Class H's most recent stock split took place on June 6, 2024 with a 5:7 split ratio.